Solaris Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Solaris Asset Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-350	Closed	-$43K	–	344
2016 Q3	$43K	Hold	350	–	–	0.03%	177
2016 Q2	$49K	Hold	350	–	–	0.04%	135
2016 Q1	$46K	Sell	350 -75	-18%	-$9.34K	0.03%	128
2015 Q4	$60K	Hold	425	–	–	0.04%	118
2015 Q3	$56K	Hold	425	–	–	0.04%	115
2015 Q2	$75K	Sell	425 -375	-47%	-$67.3K	0.05%	146
2015 Q1	$138K	Hold	800	–	–	0.09%	111
2014 Q4	$131K	Hold	800	–	–	0.08%	111
2014 Q3	$128K	Sell	800 -25	-3%	-$3.84K	0.09%	111
2014 Q2	$121K	Hold	825	–	–	0.08%	106
2014 Q1	$114K	Hold	825	–	–	0.08%	106
2013 Q4	$104K	Hold	825	–	–	0.07%	125
2013 Q3	$76K	Hold	825	–	–	0.06%	142
2013 Q2	$57K	Buy	+825	New	+$50.4K	0.05%	163

Other funds holding JAZZ

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Solaris Asset Management's JAZZ Position: Q4 2016 in Review

Solaris Asset Management sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2016, closing a stake of 350 shares — an estimated $43K sold.

Solaris Asset Management first reported a position in JAZZ in Q2 2013 and held it in 14 quarters. The position peaked at $138K in Q1 2015. 295 funds tracked by Wall St. Rank hold JAZZ as of Q4 2016.

Solaris Asset Management reported no remaining Jazz Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Solaris Asset Management sold 350 Jazz Pharmaceuticals shares in Q4 2016, an estimated $43K.
Solaris Asset Management first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 14 quarters.
Solaris Asset Management's Jazz Pharmaceuticals position peaked at $138K in Q1 2015.
295 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2016.

Based on Solaris Asset Management's 13F filing for Q4 2016, filed 25 Jan 2017.